Crossmark

Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11

Crossref DOI link: https://doi.org/10.1038/nchembio.2326

Published Online: 2017-02-28

Published Print: 2017-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Jing

Yakushi, Tanya

Parlati, Francesco

Mackinnon, Andrew L

Perez, Christian

Ma, Yuyong https://orcid.org/0000-0001-9591-6465
Carter, Kyle P

Colayco, Sharon

Magnuson, Gavin

Brown, Brock

Nguyen, Kevin

Vasile, Stefan

Suyama, Eigo

Smith, Layton H

Sergienko, Eduard

Pinkerton, Anthony B

Chung, Thomas D Y https://orcid.org/0000-0003-4856-6233
Palmer, Amy E

Pass, Ian

Hess, Sonja

Cohen, Seth M

Deshaies, Raymond J
License Information

Text and Data Mining valid from 2017-02-28
More Information

Article History

Received: 7 November 2016

Accepted: 23 January 2017

First Online: 28 February 2017

Competing interests

: R.J.D. is a founder, shareholder, consultant, and member of the Scientific Advisory Board of Cleave Biosciences, which is engaged in discovery and development of drugs that target enzymes involved in ubiquitin-dependent protein degradation. S.M.C. is a co-founder, has an equity interest, and receives income as member of the Scientific Advisory Board for Cleave Biosciences and is a co-founder, has an equity interest, and is a member of the Scientific Advisory Board for Forge Therapeutics. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.